Prognostic factors in surgical stage III and IV carcinoma of the endometrium.
OBJECTIVE
To identify prognostic factors in surgical stage III and IV endometrial carcinoma.


METHODS
We performed a retrospective analysis of 58 cases of stage III and IV endometrial cancer using the Cox proportional hazards model.


RESULTS
Extrapelvic peritoneal metastases and positive peritoneal cytology greatly affected survival. If either of these factors was present, the 2-year survival rate was only 25%, whereas if they were absent, it was 82%. All patients with extrapelvic metastases died of their disease despite systemic therapy, as did ten of 13 patients with positive peritoneal cytology. Although postoperative therapy in these patients varied, it had no obvious effect on survival or on the site of recurrence. In the absence of abdominal disease or positive peritoneal cytology, survival was not influenced significantly by the presence or absence of lymph node metastases. The difference in survival between women with aortic and pelvic lymph node metastases (24% at 5 years) was not significant, but the power to detect this difference was low (35%). Stage affected survival significantly (P < .05), but a two-category variable, indexing patients as having either positive peritoneal cytology or abdominal disease, provided a much better fit and a more parsimonious model for the data.


CONCLUSIONS
Five-year survival rates exceeding 70% can be achieved in endometrial carcinoma even if extrauterine disease is present, provided that peritoneal cytology is negative and abdominal metastases are absent.
Department of Obstetrics and Gynecology, Jersey Shore Medical Center, Neptune.
N
N
Kadar
H D
HD
Homesley
J H
JH
Malfetano
D000368:Aged; D002277:Carcinoma / Q000401:mortality / Q000473:pathology* / Q000556:secondary / Q000628:therapy; D016889:Endometrial Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate